title: [A gastric stromal tumor (GIST) with a prolonged partial response to a reduced dose of imatinib mesilate].
abstract: A 78-year-old woman was admitted to our hospital because of tarry stools. A gastric stromal tumor with liver metastasis was diagnosed. Treatment with imatinib mesilate was begun in a dose of 400 mg daily. After 1 month, the primary tumor showed a partial response; the response of the liver metastasis was stable disease. However, grade 2 edema, leukocytopenia, and anemia developed, and the dose of imatinib mesilate was reduced to 200 mg daily. The adverse reactions resolved promptly, and a partial response of both the primary tumor and liver metastasis to imatinib mesilate has been maintained for 28 months. Strategies for lowering the dose of imatinib mesilate are reviewed.
authors.affiliation: Dept. of Internal Medicine I, Kitasato University.
authors.forename: Kento
authors.initials: K
authors.lastname: Nakatani
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tanabe
authors.forename: Ken
authors.initials: K
authors.lastname: Nishimura
authors.forename: Takuya
authors.initials: T
authors.lastname: Shimoda
authors.forename: Mizutomo
authors.initials: M
authors.lastname: Azuma
authors.forename: Chikatoshi
authors.initials: C
authors.lastname: Katada
authors.forename: Toru
authors.initials: T
authors.lastname: Sasaki
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Higuchi
authors.forename: Wasaburo
authors.initials: W
authors.lastname: Koizumi
authors.forename: Katsunori
authors.initials: K
authors.lastname: Saigenji
mesh_terms: D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate